Invest with an Option to Buy: Bristol-Myers Squibb Partners with Accelerator BioMotiv

Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!!    Bristol-Myers Squibb has partnered with biotech accelerator BioMotiv. Bristol-Myers will become a limited partner, investing in projects of mutual interest, with an option to buy the companies once there is a preclinical candidate. “This new partnership will allow us to leverage the extensive expertise … Συνεχίστε να διαβάζετε Invest with an Option to Buy: Bristol-Myers Squibb Partners with Accelerator BioMotiv.

The top 10 drug launches of 2019

The top 10 drug launches of 2019

J&J’s Tremfya Superior to Novartis’ Cosentyx in Head-to-Head Trial

J&J's Tremfya Superior to Novartis' Cosentyx in Head-to-Head Trial

Pharm Exec’s 2019 Pipeline Report

Pharm Exec's 2019 Pipeline Report

FDA Approves Humira Biosimilar That Won’t Be Available Until 2023

FDA Approves Humira Biosimilar That Won’t Be Available Until 2023